Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that it will host a research and development webinar on June 15th from 9:00 AM - 11:00 AM EDT.
The event will feature presentations from the Foghorn Therapeutics management team, as well as Key Opinion Leaders Howard A. “Skip” Burris III, M.D., F.A.S.C.O., F.A.C.P., of the Sarah Cannon Research Institute, and Eytan Stein, M.D., of the Memorial Sloan Kettering Cancer Center. In addition, scientific cofounder Cigall Kadoch will discuss the biological importance of the chromatin regulatory system (CRS) in gene expression and human disease and its broad applicability in precision oncology.
The discussion will include an overview of Foghorn's Gene Traffic Control platform and pipeline.
A live question and answer session will follow the formal presentation. To register for the webinar, please click here.
Howard A. “Skip” Burris III, MD, FASCO, FACP
Dr. Burris’ clinical research career has focused on the development of new cancer agents with an emphasis on first–in–human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved. In 1997, he established the first community–based early phase drug development program in Nashville, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts.
Dr. Burris served as president of ASCO from 2019-2020 and is serving as Chairman of the Board for the 2020-2021 term. He also currently serves on the Board of ASCO’s Conquer Cancer Foundation. Additionally, in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.
Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.
Eytan Stein, M.D.
Cigall Kadoch, Ph.D.
Dr. Kadoch established her independent laboratory in 2014, at age 28, one of the youngest scientists ever appointed to the Harvard Medical School faculty, immediately following completion of her Ph.D. studies at Stanford University. She is a leading expert in chromatin and gene regulation and is internationally recognized for her groundbreaking studies in these areas. Specifically, her laboratory studies the structure and function of nuclear protein complexes that govern DNA architecture and gene expression, called chromatin remodeling complexes, perturbations in which cause a range of human cancers and neurodevelopmental disorders.
Dr. Kadoch has received numerous prestigious awards and research grants for her work, including the NIH Director’s New Innovator Award, the American Association for the Advancement of Science (AAAS) Martin and Rose Wachtel Cancer Research Prize, the American Association for Cancer Research Outstanding Achievement in Basic Cancer Research, and was recently named a finalist for the Blavatnik National Awards. Additionally, she has been named to the Forbes 30 Under 30 list, MIT Technology Review 35 Innovators Under 35, Popular Science Brilliant 10, and Business Insider Top 30 Young Leaders in Biopharma.
About Uveal Melanoma
About Foghorn Therapeutics
Gregory Kelley, Ogilvy
Investor Relations Contact:
Hans Vitzthum, LifeSci Advisors
Tips for Securing Your Remote Workforce
How to Use Asset Tracking to Enable The Smart Supply Chain: Fireside Chat w/ NimbeLink and Smart Logistics
Cloud: The Secret Sauce for Today's Workplace Realities